Transcriptomic and Proteomic Profiles for Elucidating Cisplatin Resistance in Head-and-Neck Squamous Cell Carcinoma.
HNSCC
RNA-seq
cancer
chemotherapy resistance
cisplatin
proteomics
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Nov 2022
09 Nov 2022
Historique:
received:
21
10
2022
revised:
03
11
2022
accepted:
07
11
2022
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
27
11
2022
Statut:
epublish
Résumé
To identify the novel genes involved in chemoresistance in head and neck squamous cell carcinoma (HNSCC), we explored the expression profiles of the following cisplatin (CDDP) resistant (R) versus parental (sensitive) cell lines by RNA-sequencing (RNA-seq): JHU029, HTB-43 and CCL-138. Using the parental condition as a control, 30 upregulated and 85 downregulated genes were identified for JHU029-R cells; 263 upregulated and 392 downregulated genes for HTB-43-R cells, and 154 upregulated and 68 downregulated genes for CCL-138-R cells. Moreover, we crossed-checked the RNA-seq results with the proteomic profiles of HTB-43-R (versus HTB-43) and CCL-138-R (versus CCL-138) cell lines. For the HTB-43-R cells, 21 upregulated and 72 downregulated targets overlapped between the proteomic and transcriptomic data; whereas in CCL-138-R cells, four upregulated and three downregulated targets matched. Following an extensive literature search, six genes from the RNA-seq (
Identifiants
pubmed: 36428603
pii: cancers14225511
doi: 10.3390/cancers14225511
pmc: PMC9688094
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Asociación Española Contra el Cáncer
ID : Ref. GC16173720CARR
Organisme : Instituto de Salud Carlos III
ID : PI20/00556
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Transl Res. 2022 Sep;247:58-78
pubmed: 35462077
Arch Pathol Lab Med. 2018 Apr;142(4):474-479
pubmed: 29565207
iScience. 2022 Jul 19;25(8):104777
pubmed: 35992081
Mol Cell Proteomics. 2019 Feb;18(2):231-244
pubmed: 30373788
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Cancers (Basel). 2019 Jan 08;11(1):
pubmed: 30626032
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552
pubmed: 34723319
Front Oncol. 2022 Jul 06;12:900903
pubmed: 35875133
Sci Rep. 2020 Oct 14;10(1):17258
pubmed: 33057113
Br J Cancer. 2006 Jun 19;94(12):1864-73
pubmed: 16773077
Semin Cancer Biol. 2018 Oct;52(Pt 2):228-240
pubmed: 29355614
Cell Biol Toxicol. 2022 Jul 18;:
pubmed: 35844005
J Natl Cancer Inst. 2016 Oct 5;109(1):
pubmed: 27707839
Theranostics. 2022 Jul 18;12(13):5761-5775
pubmed: 35966598
PLoS One. 2016 Jun 08;11(6):e0156651
pubmed: 27276062
Nat Rev Cancer. 2021 Oct;21(10):669-680
pubmed: 34272515
J Exp Clin Cancer Res. 2019 Jun 10;38(1):245
pubmed: 31182137
Bioinformatics. 2014 Aug 1;30(15):2114-20
pubmed: 24695404
Genome Biol. 2014;15(12):550
pubmed: 25516281
Clin Cancer Res. 2012 Sep 15;18(18):4986-96
pubmed: 22825581
Pharmacol Ther. 2017 Nov;179:127-141
pubmed: 28546082
Mol Cancer. 2022 Sep 8;21(1):178
pubmed: 36076232
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
Mol Cancer. 2012 Sep 28;11:74
pubmed: 23021083
Cell Rep. 2021 Aug 31;36(9):109621
pubmed: 34469741
Nat Commun. 2015 Apr 09;6:6744
pubmed: 25855536
Genome Biol. 2010;11(2):R14
pubmed: 20132535
Mol Cancer Ther. 2020 Aug;19(8):1708-1718
pubmed: 32430485
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Nat Commun. 2020 May 8;11(1):2285
pubmed: 32385277
FASEB J. 2020 Jul;34(7):9180-9191
pubmed: 32396246
Cell Death Dis. 2022 Apr 21;13(4):392
pubmed: 35449126
J Oral Pathol Med. 2020 Oct;49(9):897-906
pubmed: 32512620
PLoS One. 2021 Dec 23;16(12):e0261575
pubmed: 34941961
Lab Invest. 2019 Nov;99(11):1702-1713
pubmed: 31263157
Cancer Cell Int. 2022 Aug 13;22(1):254
pubmed: 35964082
Cancers (Basel). 2022 Aug 26;14(17):
pubmed: 36077671
Oncogene. 2021 Nov;40(45):6369-6380
pubmed: 34588619
Expert Rev Anticancer Ther. 2014 Jan;14(1):31-7
pubmed: 24308679
Biomed Pharmacother. 2018 Jul;103:1212-1216
pubmed: 29864900
Int J Mol Sci. 2022 Mar 30;23(7):
pubmed: 35409179
Carcinogenesis. 2019 Dec 31;40(12):1525-1534
pubmed: 31050705
Cancers (Basel). 2021 Oct 01;13(19):
pubmed: 34638436
Br J Cancer. 2021 Mar;124(7):1301-1311
pubmed: 33473168
Drug Resist Updat. 2016 May;26:1-9
pubmed: 27180306
Cancer Sci. 2022 Feb;113(2):478-488
pubmed: 34826159
PLoS One. 2012;7(9):e45534
pubmed: 23029077
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
F1000Res. 2019 Nov 7;8:1874
pubmed: 33552473
Cancers (Basel). 2020 Nov 05;12(11):
pubmed: 33167355
Curr Opin Cell Biol. 2015 Dec;37:1-8
pubmed: 26342994
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-16
pubmed: 35522916
Nature. 2015 Apr 16;520(7547):368-72
pubmed: 25807485
Biochim Biophys Acta Mol Cell Res. 2021 Jun;1868(7):119015
pubmed: 33741433
Mol Cancer Ther. 2017 Jul;16(7):1355-1365
pubmed: 28336809
Nat Commun. 2021 Apr 30;12(1):2474
pubmed: 33931648
Clin Immunol. 2022 Jul;240:109045
pubmed: 35618211
J Biol Chem. 2015 Dec 4;290(49):29652-62
pubmed: 26468294
Oncotarget. 2016 Nov 15;7(46):76087-76100
pubmed: 27738319